source
- TRex Bio prices $117M IPO to fund Treg-targeted immune therapiesTRex Bio announced pricing of its initial public offering at $117 million, selling 8,333,334 shares at $14 each, meeting the low end of its earlier guidance. The company will begin trading on Nasd…
- City Therapeutics plans $158 million IPO as Iambic eyes $135 million Nasdaq debutCity Therapeutics, an RNAi startup founded by former Alnylam Pharmaceuticals executives, announced plans for an initial public offering targeting roughly $158 million. The company intends to sell a…